In addition, the diagnostic efficiency of serum EFNA1 combined with MMP13 (AUC 0.794, sensitivity 55.7%, specificity 90.2%) in GC patients was significantly higher than the two single tests (EFNA1 (AUC 0.723, sensitivity 42.6%, specificity 90.2%), MMP13 (AUC 0.761, sensitivity 47.0%, specificity 90.2%)) (Fig. 3A and Table 3). This evidence concerns the gene MMP13 and gastric cancer.